Thus, antagonists of TMEM16A and repositioning of niclosamide and nitazoxanide represent an important additional treatment for patients with severe asthma and COPD that is poorly controlled with existing therapies. This evidence concerns the gene ANO1 and chronic obstructive pulmonary disease.